Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 9/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16082519 | 0.91 | TP53 (0.65) | TP53ATMLMNAHPGDMEN1 | |
| SCHEMBL17480781 | 0.86 | ATM (0.71) | TP53ATMLMNAHPGDMEN1 | |
| SCHEMBL16082491 | 0.77 | TP53 (0.85) | TP53ATMLMNAHPGDMEN1 | |
| SCHEMBL8395697 | 0.73 | TP53 (0.51) | TP53ATMHPGDMEN1KMT2A | |
| SCHEMBL10817145 | 0.72 | PDE10A (0.56) | TP53ATM | |
| SCHEMBL8396137 | 0.69 | HSD17B10 (0.47) | — | |
| SCHEMBL17480775 | 0.69 | TP53 (0.70) | TP53LMNAHPGDMEN1KMT2A | |
| SCHEMBL8397132 | 0.68 | AGTR1 (0.47) | — | |
| SCHEMBL16082483 | 0.68 | TP53 (0.79) | TP53LMNAHPGDMEN1KMT2A | |
| SCHEMBL16082518 | 0.68 | TP53 (1.00) | TP53LMNAHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031824-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031824-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | TARDBP, ADRM1, MDM2 | TP53 50/4885ATM 2338/4885LMNA 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.